- Home
- EXTR vs AKRO Comparison
EXTR vs AKRO Comparison
Compare EXTR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXTR | AKRO |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 4.5B |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EXTR | AKRO |
|---|---|---|
| Price | $16.90 | $54.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $21.80 | ★ $73.56 |
| AVG Volume (30 Days) | 1.2M | ★ 2.4M |
| Earning Date | 01-28-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,181,108,000.00 | N/A |
| Revenue This Year | $12.45 | N/A |
| Revenue Next Year | $7.33 | N/A |
| P/E Ratio | $290.33 | ★ N/A |
| Revenue Growth | ★ 14.31 | N/A |
| 52 Week Low | $10.10 | $21.34 |
| 52 Week High | $22.89 | $58.40 |
Technical Indicators
Market Signals| Indicator | EXTR | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 68.63 |
| Support Level | $16.99 | $54.30 |
| Resistance Level | $18.36 | $54.70 |
| Average True Range (ATR) | 0.46 | 0.17 |
| MACD | 0.10 | -0.10 |
| Stochastic Oscillator | 2.67 | 71.07 |
Price Performance
Historical ComparisonAbout EXTR Extreme Networks Inc.
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.